FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4





FIGURE 5



Days post 1st dose

FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10




FIGURE 11



Expression normalized binding
35
30
25
20
15
10
5
0
JS4896
JS5340
JS5342
JS5347
JS5358
1nM
10nM
100nM

FIGURE 12



Probody Binding ELISA
4D11
5342 NSub
Abs450
[nM]
Probody Binding ELISA
4D11
5342 1203
Abs450
[nM]
Probody Binding ELISA
4D11
5342 1204
Abs450
[nM]
Probody Binding ELISA
4D11
5342 1214
Abs450
[nM]
Probody Binding ELISA
4D11
5342 PLGL
Abs450
[nM]

FIGURE 13




FIGURE 14




FIGURE 15



% initial body weight
Vehicle
4D11 6.7 mg/kg
4D11 20 mg/kg
5342-Nsub 20 mg/kg
5342-1203 20 mg/kg
5342-1204 20 mg/kg
5342-1214 20 mg/kg
5342-PLGL 20 mg/kg
% initial body weight
= dose
= mouse found dead
Days post tumor inoculation

FIGURE 16A




FIGURE 16B




FIGURE 17




FIGURE 18




FIGURE 19




FIGURE 20



4D11-AF680
1204-4D11-AF680
P1GL-4D11-AF680
Without Inhibitor
With Inhibitor*
* - Broad spectrum protease inhibitors cocktail

FIGURE 21




No Inhibitor
Matriptase Inhibitor
MMP Inhibitor
Broad Spec.*
4D11
1204
PLGL
* - Broad spectrum protease inhibitors cocktail

FIGURE 22


A
Epi-fluorescence
4.5
4.0
x10^6
3.5
Radiant Efficiency
[p/sec/cm²/sr / µW/cm²]
Color Scale
Min = 3.15e6
Max = 4.74e6



B
Average T/N
Average Radiant Efficacy ROI
8
6
4
2
0
0
20
40
60
80
Time (h)

FIGURE 23




FIGURE 24




FIGURE 25




FIGURE 26




FIGURE 27A

Clone	hJag1	hJag2
125.14		+++
125.15	++	
346.4	++	
346.5	++	
346.7	+++	+++
346.8	+	
346.13		++
346.16	+++	+
346.19	+	
346.21	+	
346.24	+	+

Clone	hJag1	hJag2
346.26	++	
346.27	++	
346.28	+++	+++
346.30		++
346.31	++	
346.32		+
346.37	+	
346.39	+	+++
346.40	+++	++
346.47		+++

FIGURE 27B

Fab	Kd (nM)			
	hJAG1	hJAG2	rJAG1	rJAG2
Parental	63	35	53	ND
Matured	<1	<1	<1	<1

FIGURE 27C



Relative Notch 1 Activity (% Control)
100
80
60
40
20
0
-2
-1
0
1
2
3
4
[Fab] (log nM)
Matured Fab
Relative Notch 1 Activity (% Control)
100
80
60
40
20
0
0.01
0.1
1
10
100
1000
[Fab] (nM)
Matured IgG: hJAG1, hJAG2, rJAG1

FIGURE 28




FIGURE 29




FIGURE 30



Group-1 Vehicle 10 uL/g Q7Dx4 i.p.
Group-2 Gemcitabine 150 mg/kg 10 uL/g Q7Dx4 i.p.
Group-3 4D11 2 mg/kg Gemcitabine 100 mg/kg 10 uL/g Q7Dx4 i.p.
Group-4 4D11 6.7 mg/kg Gemcitabine 100 mg/kg 10 uL/g Q7Dx4 i.p.
Group-5 4D11 20 mg/kg Gemcitabine 100 mg/kg 10 uL/g Q7Dx2 i.p.
Group-6 5342-1204-4D11 2 mg/kg Gemcitabine 100 mg/kg 10 uL/g Q7Dx4 i.p.
Group-7 5342-1204-4D11 6.7 mg/kg Gemcitabine 100 mg/kg 10 uL/g Q7Dx4 i.p.
Group-8 5342-1204-4D11 20 mg/kg Gemcitabine 100 mg/kg 10 uL/g Q7Dx4 i.p.
Body Weight change (%)
150
140
130
120
110
100
90
80
70
28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62 64 66 68 70
Days after Tumor Inoculation

FIGURE 31




FIGURE 32




FIGURE 33




FIGURE 34




FIGURE 35




FIGURE 36




FIGURE 37




FIGURE 38




FIGURE 39

